Logo image of ELUT

ELUTIA INC (ELUT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ELUT - US05479K1060 - Common Stock

0.723 USD
+0.03 (+4.71%)
Last: 1/9/2026, 8:00:01 PM
0.729 USD
+0.01 (+0.83%)
After Hours: 1/9/2026, 8:00:01 PM
Fundamental Rating

1

Overall ELUT gets a fundamental rating of 1 out of 10. We evaluated ELUT against 530 industry peers in the Biotechnology industry. ELUT has a bad profitability rating. Also its financial health evaluation is rather negative. ELUT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ELUT had negative earnings in the past year.
ELUT had a negative operating cash flow in the past year.
ELUT had negative earnings in each of the past 5 years.
In the past 5 years ELUT always reported negative operating cash flow.
ELUT Yearly Net Income VS EBIT VS OCF VS FCFELUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -90.02%, ELUT is not doing good in the industry: 72.45% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -90.02%
ROE N/A
ROIC N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELUT Yearly ROA, ROE, ROICELUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K -3K -4K

1.3 Margins

With a decent Gross Margin value of 45.97%, ELUT is doing good in the industry, outperforming 74.72% of the companies in the same industry.
ELUT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ELUT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
ELUT Yearly Profit, Operating, Gross MarginsELUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

0

2. Health

2.1 Basic Checks

ELUT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ELUT has been increased compared to 1 year ago.
Compared to 5 years ago, ELUT has more shares outstanding
The debt/assets ratio for ELUT is higher compared to a year ago.
ELUT Yearly Shares OutstandingELUT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ELUT Yearly Total Debt VS Total AssetsELUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ELUT has an Altman-Z score of -14.14. This is a bad value and indicates that ELUT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.14, ELUT is doing worse than 78.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.14
ROIC/WACCN/A
WACC14.02%
ELUT Yearly LT Debt VS Equity VS FCFELUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 0.44 indicates that ELUT may have some problems paying its short term obligations.
ELUT has a worse Current ratio (0.44) than 90.57% of its industry peers.
ELUT has a Quick Ratio of 0.44. This is a bad value and indicates that ELUT is not financially healthy enough and could expect problems in meeting its short term obligations.
ELUT's Quick ratio of 0.40 is on the low side compared to the rest of the industry. ELUT is outperformed by 90.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.4
ELUT Yearly Current Assets VS Current LiabilitesELUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2

3. Growth

3.1 Past

ELUT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.95%, which is quite impressive.
Looking at the last year, ELUT shows a very negative growth in Revenue. The Revenue has decreased by -33.02% in the last year.
ELUT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.69% yearly.
EPS 1Y (TTM)73.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
Revenue 1Y (TTM)-33.02%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-43.89%

3.2 Future

ELUT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.61% yearly.
The Revenue is expected to decrease by -8.34% on average over the next years.
EPS Next Y81.62%
EPS Next 2Y33.85%
EPS Next 3Y22.61%
EPS Next 5YN/A
Revenue Next Year-24.6%
Revenue Next 2Y-21.45%
Revenue Next 3Y-8.34%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ELUT Yearly Revenue VS EstimatesELUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
ELUT Yearly EPS VS EstimatesELUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

1

4. Valuation

4.1 Price/Earnings Ratio

ELUT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ELUT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELUT Price Earnings VS Forward Price EarningsELUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELUT Per share dataELUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

ELUT's earnings are expected to grow with 22.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.85%
EPS Next 3Y22.61%

0

5. Dividend

5.1 Amount

No dividends for ELUT!.
Industry RankSector Rank
Dividend Yield 0%

ELUTIA INC

NASDAQ:ELUT (1/9/2026, 8:00:01 PM)

After market: 0.729 +0.01 (+0.83%)

0.723

+0.03 (+4.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2025-11-09/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners39.76%
Inst Owner ChangeN/A
Ins Owners2.92%
Ins Owner Change8.36%
Market Cap30.87M
Revenue(TTM)21.08M
Net Income(TTM)-26.47M
Analysts82.5
Price Target3.57 (393.78%)
Short Float %0.31%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.22%
Min EPS beat(2)-32.64%
Max EPS beat(2)43.07%
EPS beat(4)2
Avg EPS beat(4)15.16%
Min EPS beat(4)-32.64%
Max EPS beat(4)52.18%
EPS beat(8)3
Avg EPS beat(8)-32.92%
EPS beat(12)5
Avg EPS beat(12)-27.63%
EPS beat(16)6
Avg EPS beat(16)-23.29%
Revenue beat(2)0
Avg Revenue beat(2)-28.63%
Min Revenue beat(2)-51.01%
Max Revenue beat(2)-6.26%
Revenue beat(4)0
Avg Revenue beat(4)-19.38%
Min Revenue beat(4)-51.01%
Max Revenue beat(4)-6.26%
Revenue beat(8)1
Avg Revenue beat(8)-12.66%
Revenue beat(12)2
Avg Revenue beat(12)-9.2%
Revenue beat(16)4
Avg Revenue beat(16)-6.52%
PT rev (1m)0%
PT rev (3m)-36.36%
EPS NQ rev (1m)11.11%
EPS NQ rev (3m)11.11%
EPS NY rev (1m)16.04%
EPS NY rev (3m)25.83%
Revenue NQ rev (1m)10.71%
Revenue NQ rev (3m)-65.17%
Revenue NY rev (1m)-6.27%
Revenue NY rev (3m)-23.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.46
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.68
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0.49
BVpS-1.03
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -90.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.97%
FCFM N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
F-Score3
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.32%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.44
Quick Ratio 0.4
Altman-Z -14.14
F-Score3
WACC14.02%
ROIC/WACCN/A
Cap/Depr(3y)14.22%
Cap/Depr(5y)13.83%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
EPS Next Y81.62%
EPS Next 2Y33.85%
EPS Next 3Y22.61%
EPS Next 5YN/A
Revenue 1Y (TTM)-33.02%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-43.89%
Revenue Next Year-24.6%
Revenue Next 2Y-21.45%
Revenue Next 3Y-8.34%
Revenue Next 5YN/A
EBIT growth 1Y10.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.81%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-83.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.24%
OCF growth 3YN/A
OCF growth 5YN/A

ELUTIA INC / ELUT FAQ

Can you provide the ChartMill fundamental rating for ELUTIA INC?

ChartMill assigns a fundamental rating of 1 / 10 to ELUT.


Can you provide the valuation status for ELUTIA INC?

ChartMill assigns a valuation rating of 1 / 10 to ELUTIA INC (ELUT). This can be considered as Overvalued.


Can you provide the profitability details for ELUTIA INC?

ELUTIA INC (ELUT) has a profitability rating of 1 / 10.


How financially healthy is ELUTIA INC?

The financial health rating of ELUTIA INC (ELUT) is 0 / 10.